Story thread · 2 reports / 2 sources

Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds

cancerletter.com · 11dShare

Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to the results of an international phase III clinical trial. This content is for Group 1 - Individual Seat, Individual Subscription - Annual ($555), […] The post Enfortumab vedotin + pembrolizumab improves survival and reduces recurrence risk in muscle-invasive bladder cancer, phase III trial finds appeared first on The Cancer Letter .

First report: Bladder Cancer Rx-Induced Skin Reactions Affect Survival — medscape.com, 11d